ClinicalTrials.gg
RecruitingNCT06234410CRAFT-CTCAUpdated Nov 5, 2026

Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation

An observational study in Cardiovascular Diseases and Kidney Transplant; Complications, sponsored by University of Edinburgh. Recruiting at 5 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Edinburgh · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Nov 5, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
332
Ages
16 Years and older
Sex
All
01

Study summary

Cardiovascular disease (for example, heart attack, stroke, heart failure) is the commonest complication of kidney failure. Kidney transplantation reduces cardiovascular risk but cardiovascular disease remains the commonest cause of death in patients following transplantation.

Current strategies to assess patient's cardiovascular risk prior to kidney transplantation do not identify those at highest risk and do not improve outcomes.

This study will use a heart scan known as computed tomography coronary angiography (CTCA) to see whether this scan can identify patients at highest risk of future cardiovascular disease prior to transplantation. Studies have shown it is able to do this in patients with normal kidney function.

The aim of this study is to develop CTCA as an effective tool to risk stratify patients prior to kidney transplantation.

02

Conditions studied

  • Cardiovascular Diseases
  • Kidney Transplant; Complications

Keywords

  • Coronary artery disease
  • Kidney transplantation
  • Cardiovascular risk assessment
  • Heart disease
  • Chronic kidney disease
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 332 is below the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients on the kidney transplant waitlist

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has kidney failure and is on the waitlist for a kidney transplant
  • Age 16 years and over
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • to CT scanning, including contrast allergy
  • Patients being considered for a simultaneous kidney-pancreas, kidney-liver and/or kidney-islet transplantation
  • Inability to give
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
332 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients waitlisted for kidney transplantation

    Patients who have been placed on the waiting list for a kidney transplant within Scotland

    Radiation: Computed tomography coronary angiography (CTCA)

Interventions

  • RadiationComputed tomography coronary angiography (CTCA)

    Single CTCA scan prior to kidney transplantation

06

What researchers measure

Primary outcomes

  1. Number of participants who have either a myocardial infarction or cardiovascular death

    The first event of myocardial infarction or cardiovascular death

    Time frame: From time of CTCA scan to 36- and 60-months follow-up

Secondary outcomes

  1. Number of participants who have a fatal or non-fatal myocardial infarction

    The first event of myocardial infarction (MI). MI will be defined according to the 4th Universal Definition of Myocardial Infarction.

    Time frame: From time of CTCA scan to 36- and 60-months follow-up

  2. Number of participants who are hospitalised due to any cardiovascular event

    Hospital admission due to any cardiovascular event (including myocardial infarction, heart failure, stroke, or any other cardiovascular disease)

    Time frame: From time of CTCA scan to 36- and 60-months follow-up

  3. Number of participants who die (all-cause death)

    Death due to any cause

    Time frame: From time of CTCA scan to 36- and 60-months follow-up

  4. Number of participants who have a cardiovascular death

    Death due to a cardiovascular cause (including myocardial infarction, heart failure, stroke, or any other cardiovascular disease)

    Time frame: From time of CTCA scan to 36- and 60-months follow-up

Other outcomes

  1. Number of participants who suffer a clinically significant acute kidney injury following study CTCA scan

    Unexpected progression to dialysis (haemodialysis or peritoneal dialysis) within 28 days of study CTCA scan

    Time frame: From time of CTCA scan to 28 days follow-up

  2. Number of participants who have clinically significant abnormal non-cardiac findings on study CTCA scan

    Abnormal non-cardiac findings (e.g., lung mass), not related to a pre-existing condition and requiring further investigation

    Time frame: From time of CTCA scan to 12 months follow-up

07

Study locations

5 of 5 sites recruiting
  • Royal Infirmary of Edinburgh
    Edinburgh, Lothian EH16 4SA, United Kingdom
    Recruiting
    • Gavin B Chapman, MBChB · Contactgchapma2@ed.ac.uk · 00447713349318
    • Gavin B Chapman, MBChB · Sub investigator
    • Neeraj Dhaun, MBChB · Principal investigator
    • Nicholas Mills, MBChB · Sub investigator
    • Michelle Williams, MBChB · Sub investigator
  • Queen Elizabeth Hospital
    Glasgow, G51 4TF, United Kingdom
    Recruiting
    • Rajan Patel, MBChB · ContactRajan.Patel2@nhs.scot
    • Patrick Mark, MBChB · Sub investigator
    • Rajan Patel, MBChB · Principal investigator
    • Gavin Chapman, MBChB · Sub investigator
    • Giles Roditi, MBChB · Sub investigator
  • Imperial College Healthcare NHS Trust
    London, United Kingdom
    Recruiting
    • Christopher Baker · Contactchristopher.baker1@nhs.net · +442033131928
    • Christopher Baker · Principal investigator
    • Michelle Willicombe · Sub investigator
  • University Hospitals Plymouth NHS Trust
    Plymouth, United Kingdom
    Recruiting
    • Kris Houlberg · Contactkris.houlberg@nhs.net · +441752432842
    • Kris Houlberg · Principal investigator
  • Sheffield Teaching Hospitals NHS Trust
    Sheffield, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Following publication of the primary paper, a deidentified individual participant data set will be will be made available for data sharing purposes, subject to necessary governance approvals. Access to the deidentified dataset will be under a controlled access model.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2032, 96 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 96 months is above that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Jan 31, 2024
StartActual
Jan 24, 2024
Primary completionEst.
Jan 2032
CompletionEst.
Jan 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. Queen Elizabeth Hospital is now Recruiting
Show 3 added (3 United Kingdom)
  • Imperial College Healthcare NHS Trust · London, United Kingdom
  • University Hospitals Plymouth NHS Trust · Plymouth, United Kingdom
  • Sheffield Teaching Hospitals NHS Trust · Sheffield, United Kingdom
Nov 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Queen Elizabeth Hospital · Glasgow, United KingdomContact p•••@glasgow.ac.uk→R•••@nhs.scotContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    3 sites added. Queen Elizabeth Hospital is now Recruiting
    Show 3 added (3 United Kingdom)
    • Imperial College Healthcare NHS Trust · London, United Kingdom
    • University Hospitals Plymouth NHS Trust · Plymouth, United Kingdom
    • Sheffield Teaching Hospitals NHS Trust · Sheffield, United Kingdom
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Queen Elizabeth Hospital · Glasgow, United KingdomContact p•••@glasgow.ac.uk→R•••@nhs.scotContact person changed (no phone or email listed)Contact person changed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06234410
Collaborators
Chief Scientist Office of the Scottish Government, University of Glasgow, NHS Lothian, NHS Greater Glasgow and Clyde
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Jan 24, 2024
Primary completion
Jan 2032 (estimated)
Completion
Jan 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

Gavin B Chapman, MBChB
Contact
gchapma2@ed.ac.uk
00447713349318
Neeraj Dhaun, MBChB
Contact
bean.dhaun@ed.ac.uk
Neeraj Dhaun, MBChB
principal investigator · University of Edinburgh

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion